Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Sudden death prevention Top 5 new things clinicians should know
Dan Musat, MDArrhythmia Institute of the
Valley Health System02/08/2019
Disclosures
• None
Definitions
• CARDIAC ARREST is the cessation of cardiac mechanical activity, as confirmed by the absence of signs of circulation.
• SUDDEN CARDIAC ARREST - unexpected cardiac arrest with attempts to restore circulation.
• If attempts are unsuccessful, this situation is referred to as SUDDEN CARDIAC DEATH
• We wish it would be so easy!
The New Things…
• 1. Did SCD occurrence changed over years?• 2. Are all the cardiomyopathies the same?• 3. Does LifeVest save lives?• 4. New CMS requirements for ICD implantation• 5. Current new and future developments in risk
stratification of sudden cardiac death
SCD Statistics
Sudden cardiac death is the largest cause of natural death in the United States
110.8 individuals per 100,000 population
Lifetime risk of SCD – 1 in 7.5 people
366,494 persons
Risk factors- CAD and structural heart disease- Young males- Low socioeconomic status- Smoking- Exercise- Diet- Weight- Depression
SCD – Age and Over the years
Age-specific death rates for any mention of sudden cardiac death by age, 2016
Age-adjusted death rates for any mention of sudden cardiac death, 1999 to 2016
Benjamin, Heart Disease and Stroke Statistics—2019 Update Circulation. 2019;139:00–00. DOI: 10.1161
Why did it improve?
• CAD and structural heart disease – major risk factors• Better prevention
– Smoking cessation
– Treatment of risk factors – hypertension, diabetes, hyperlipidemia
• Better treatment– STEMI/NSTEMI
– Cardiomyopathies – beta-blockers, ACEI/ARB, Aldosterone inhibitors
• Needs improvement– Obesity
– Fitness
2. Cardiomyopathies Are all the same?
Ischemic Dilated Other
HCM
Is this patient with MI at risk for SCD?
• 72-year-old man with hypertension, smoker and COPD suffered an antero-lateral STEMI for which he underwent PCI with 2 stents to proximal LAD and D1. LVEF 25% with evidence of antero-lateral scar, class I heart failure symptoms.
• During hospitalization he has episodes of non-sustained ventricular tachycardia up to 20 beats, asymptomatic, > 48 hours post intervention.
What should be the next step?
• 1. Insert ICD at this time• 2. Treat medically for 3 months and ICD
implantation if LVEF still < 30%• 3. Wearable defibrillator (LifeVest) until ICD is
implanted in 3 months• 4. EP study and if VT inducible ICD
implantation now
Risk of SCD after MI
Solomon S N Engl J Med 2005;352:2581-8
ICD immediate after AMI
DINAMIT IRIS
3. Does Life Vest Saves Lives?
VEST 1524 randomly assigned to vest778 randomly assigned to control
Primary outcome:SCD from VT at 90 days
VEST on treatment analysis
Dilated Cardiomyopathy
Kadish A N Engl J Med 2004;350:2151-8
Bady N Engl J Med 2005; 352:225-237
DEFINITE SCD-HEFT
Dilated Cardiomyopathy
Kobec N Engl J Med 2016;375:1221-30
DANISH
Goldberger J Am Coll Cardiol 2014;63:1879–89
Annual Rate of the Arrhythmic Endpoint Based on LGE
Di Marco et al. J Am Coll Cardiol HF 2017;5:28–38
Risk of SCD based on LGE
Di Marco et al. J Am Coll Cardiol HF 2017;5:28–38
4. New CMS requirements for ICD implantation
5. Current and future developments in risk stratification of sudden cardiac death
HCM – LGE on CMR MARVEN Study
1) Validate the MADIT-CRT-derived model predicting fast VT/VF in nonischemiccardiomyopathy patients with QRS≥120 ms.
2) Determine whether CMR added to the risk model validated in specific aim 1 will further improve risk stratification for predicting fast VT/VF in nonischemiccardiomyopathy patients with QRS≥120ms.
Genetics in evaluating the future risk for SCD
• Myocardial fibrosis is a common postmortem finding among young individuals with sudden cardiac death
• 4031 consecutive individuals with sudden cardiac death in Northern Finland, among whom PMF was the only structural finding in 145 subjects with sudden cardiac death
• 96 specimens with DNA - genetic tests identified 24 variants of known or uncertain significance in 26 subjects (27%). – 10 were pathogenic/likely pathogenic variants in 10 subjects (10%)
• 5 – ARVC (ACM)• 6 – HCM• 11 - DCM
– 14 were variants of uncertain significance in 11 genes among 16 subjects (17%)